HE4 References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.

  2. McGowan L, Lesher LP, Norris HJ, Barnett M. Misstaging of ovarian cancer. Obstet Gynecol 1985;65(4):568-72.

  3. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol. 2000;78(3 Pt 2):S1-S13.

  4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50(1):7-33.

  5. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100(6):1413-1416.

  6. Ovarian Cancer National Alliance. Ovarian cancer statistics. http://www.ovariancancer.org/about/statistics/

  7. Ovarian Cancer National Alliance. Risk factors. http://www.ovariancancer.org/about/risk-factors/
  8. Moore RG, Brown AK, Miller CM, et al. The use of multiple novel serum tumor markers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402-408.

  9. CA125II™ Radioimmunoassay [Product insert], Fujirebio Diagnostics, Inc.

  10. Ovarian Cancer National Alliance. Seeking the care of a gynecologic oncologist. http://www.ovariancancer.org/about/treatment/

  11. Moore RG, Bast RC Jr. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol. 2007;25(27):4159-4161.

  12. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995;273(6):491-497.

  13. National Comprehensive Cancer Network. NCCN practice guidelines in oncology—v.1.2006.

  14. Knapp RC, Jacobs I, Schwartz, P. Clinical perspectives on the use of the CA125 radioimmunoassay in ovarian cancer. Contemp Ob Gyn. 1996;41:99.

  15. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 2000;70(2):209-262.
  16. American Cancer Society. What are the key statistics about ovarian cancer? http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-key-statistics

  17. HE4 EIA [Package insert], Fujirebio Diagnostics, Inc.

  18. Data on File [Pelvic mass algorithm report], Fujirebio Diagnostics, Inc.

  19. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA125II: reliable second-generation immunoassay for determining CA125 in serum. Clin Chem. 1993;39(12):2509-2513.

  20. Data on File [Clinical Data Report], Fujirebio Diagnostics, Inc.

  21. Moore RG, Miller, MC, Disilverstro P; et al. Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass. Obstetrics & Gynecology. 118(2, Part 1):280-288, August 2011.

  22. WHO International Agency for Reseach on Cancer - EUCAN Statistics for Ovarian cancer. http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=27&Gender=2

  23. ESMO Clinical Practice Guidelines: Gynaecological Cancers. http://www.esmo.org/Guidelines/Gynaecological-Cancers


You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Please log in to react

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.